Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Average Rating of “Moderate Buy” from Brokerages

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has received an average rating of “Moderate Buy” from the seventeen research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $214.5714.

Several equities research analysts have recently commented on the stock. Wells Fargo & Company lifted their price objective on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. UBS Group restated a “neutral” rating and issued a $188.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Monday, November 24th. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Morgan Stanley increased their price objective on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $219.00 target price (up from $147.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, December 10th.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,117 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $190.91, for a total transaction of $213,246.47. Following the completion of the transaction, the chief accounting officer directly owned 9,235 shares in the company, valued at $1,763,053.85. The trade was a 10.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Norbert G. Riedel sold 3,415 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $192.00, for a total transaction of $655,680.00. Following the completion of the sale, the director directly owned 7,024 shares in the company, valued at approximately $1,348,608. The trade was a 32.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 73,626 shares of company stock valued at $13,979,198. 4.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of JAZZ. Royal Bank of Canada raised its position in Jazz Pharmaceuticals by 96.5% during the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after acquiring an additional 33,210 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after purchasing an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Jazz Pharmaceuticals by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after purchasing an additional 7,954 shares in the last quarter. Focus Partners Wealth lifted its stake in shares of Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after purchasing an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals News Roundup

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Barclays started research coverage of Jazz, which can raise visibility and institutional interest and is a modest positive for sentiment. Jazz Pharmaceuticals (NASDAQ:JAZZ) Research Coverage Started at Barclays
• Neutral Sentiment: Management presented at the TD Cowen Health Care Conference; the transcript provides updates on strategy and pipeline but did not announce major new approvals or guidance changes likely to move the stock immediately. Conference Transcript
• Neutral Sentiment: A Zacks note discusses Jazz’s reliance on international sales and how revenue mix could affect analyst forecasts — useful for modeling risk/benefit but not an immediate catalyst unless estimates are revised. Zacks International Sales Analysis
• Negative Sentiment: Large insider sale by EVP Neena M. Patil: 55,600 shares sold (~$10.65M at ~ $191.56/share), representing roughly a 49% reduction in her stake — a sizable single insider liquidation that can pressure sentiment. Neena M. Patil SEC Filing
• Negative Sentiment: Additional senior insider sales: SVP Mary Elizabeth Henderson sold 5,343 shares (~$1.04M) and Director Norbert G. Riedel sold 3,415 shares (~$655.7K); these are meaningful percentage reductions and add to downward pressure. Mary E. Henderson SEC Filing Norbert G. Riedel SEC Filing
• Negative Sentiment: CAO Patricia Carr executed multiple sales (1,253 and 1,117 shares recently), a smaller but repeated reduction that contributes to the pattern of insider selling. Patricia Carr Insider Trades

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $186.67 on Wednesday. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $198.00. The company has a market cap of $11.49 billion, a PE ratio of -31.27, a P/E/G ratio of 0.38 and a beta of 0.22. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86. The business has a 50-day simple moving average of $170.40 and a two-hundred day simple moving average of $152.93.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, beating the consensus estimate of $6.49 by $0.15. The firm had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. Jazz Pharmaceuticals’s revenue was up 8.1% on a year-over-year basis. During the same period last year, the firm posted $6.51 EPS. As a group, equities analysts expect that Jazz Pharmaceuticals will post 16.96 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.